T-CELL IMMUNE PHENOTYPING FOR DIFFERENTIAL DIAGNOSIS OF CROHN'S DISEASE ASSOCIATED ANORECTAL FISTULA: A PILOT STUDY

Our aim was to develop a system of parameters that could, enable differentiation between idiopathic and Crohn’s disease (CD) associated fistula without intestinal lesions. 28 healthy individuals, 9 patients with idiopathic fistula and 12 patients with Crohn’s fistula participated in our study. We evaluated different peripheral blood T-cell populations by means of flow cytometry. CD62L^lowCD45RA+ effector T-cells were increased in the idiopathic fistula cases (p<0,05) and decreased in Crohn’s fistula cases (p<0,01) compared with the control 9roup. On the contrary, naïve CD62L^highCD45RA+ T-cells were higher in the idiopathic fistula group and lower in Crohn’s fistula cases (p<0,01). No difference between CD4+CD69+, CD4+CD161^high and CD4+CD161^low Т-cell levels was shown between healthy controls and Crohn’s fistula cases, however, CD4+CD161^high and CD4+CD161^low T-cell levels were lower (p< 0,01 and p < 0,05, respectively) and CD4+CD69+ T-cell levels were higher (p<0,01) in the group of idiopathic fistulas compared with the control. Moreover, Crohn’s fistulas showed the decrease of CD8+CD25+ T-cell level (p<0,01) and the increase of CD8+CD161^high T-cell absolute count (p<0,05) compared with idiopathic0 fistula cases. Thus peripheral T-cell immune phenotypin9 seems to be promising for early identification of CD that manifests as an isolated anorectalfistula.

MAIT-клетки, iNKT-клетки, CD25+ Т-лимфоциты, CD69+ Т-лимфоциты, anorectalfistula, Crohn's disease, biomarkers, MAIT-cells, Th17, iNKT, naïve T-cells, effector T-cells, CD25+ T-cells, CD69+ T-cells

1. Blumetti J., Cintron J.R. Anorectal Abscess and Fistula. In: Current Surgical Therapy., Saunders, an imprint of Elsevier Inc. - 265-274.

2. Головенко А.О., Халиф И.Л., Головенко О.В. Профилактика послеоперационных рецидивов болезни Крона (обзор литературы). Колопроктология. - 2012. - 4 (42). - с. 40-48.

3. Конович Е.А., Халиф И.Л., Шапина М.В. Иммунопатогенез воспалительных заболеваний кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2013. -т. 23. - № 4. - с. 69-78.

4. Juncadella A.C., Alame A.M., Sands L.R. et al. Perianal Crohn’s disease: A review. Postgraduate Medicine. - 2015; 127 (3), 266-272.

5. Scharl M., Rogler G. Pathophysiology of fistula formation in Crohn’s disease. World Journal of Gastrointestinal Pathophysiology. - 2014; 5 (3), 205-212.

6. Atienza P., Ksiaa M. Particular aspects of proctology for anoperineal lesions in Crohn’s disease. Journal of Visceral Surgery. - 2015; 152 (2 Suppl), S45-53.

7. Nielsen O.H., Rogler G., Hahnloser D. Diagnosis and management of fistulizing Crohn’s disease. Nature Clinical Practice. Gastroenterology & Hepatology. - 2009; 6 (2), 92-106.

8. Халиф И.Л., Шапина М.В. Биологическая (антицитокиновая) терапия при болезни Крона: эффективность и потеря ответа. Доказательная гастроэнтерология. - 2013. - № 3. - c. 17-23. КОЛОПРОКТОЛОГИЯ, 2016, № 4 (58)

9. Chighnen J., Fleisher T.A., Shearer W.T. Adaptive Immunity. In: Middleton’s Allergy: Principles and Practice, 2, 20-29, Saunders, an imprint of Elsevier Inc.

10. Golubovskaya V., Wu L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers (Basel). - 2016 Mar.; 15; 8 (3).

11. Busch D.H., Fräßle S.P., Sommermeyer D. et al. Role of memory T cell subsets for adoptive immunotherapy. Semin. Immunol. - 2016; Feb; 28 (1): 28-34.

12. Fonseca-Camarillo G., Yamamoto-Furusho J.K. Immunoregulatory Pathways Involved in Inflammatory Bowel Disease. Inflamm. Bowel Dis. - 2015 Sep; 21 (9): 2188-93.

13. Хайдуков С.В., Байдун Л.В. Современные подходы к оценке клеточной составляющей иммунного статуса. Медицинский алфавит. - 2015. - т. 2. -№ 8. - с. 44-51.

14. Radulovic K., Niess J.H. CD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment? J. Immunol. Res. - 2015; 2015: 497-506.

15. Highrahara K., Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int. Immunol. - 2016 Apr; 28 (4): 163-71.

16. Fergusson J.R., Smith K.E., Fleming V.M. et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep. - 2014 Nov; 9 (3): 1075-88.

17. Cowley S.C. MAIT cells and pathogen defense. Cell Mol Life Sci. - 2014 Dec; 71 (24): 4831-40.

18. Ussher J.E., Bilton M., Attwod E. et al. CD161 + CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur. J. Immunol. - 2014 Jan; 44 (1): 195-203.

19. Birkholz A.M., Kronenberg M. Antigen specificity of invariant natural killer T-cells. Biomed. J. - 2015 Dec; 38 (6): 470-83.

20. Zajonc D.M., Girardi E. Recognition of Microbial Glycolipids by Natural Killer T Cells. Front. Immunol. -2015 Aug; 6: 400.

21. Kinjo Y., Kitano N., Kronenberg M. The role of invariant natural killer T cells in microbial immunity. J. Infect. Chemother. - 2013 Aug; 19 (4): 560-70.

22. Fergusson J.R., Hühn M.H., Swadling L. et al. CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched withighn the gut. Mucosal Immunol. - 2016 Mar; 9 (2): 401-13.

23. Churlaud G., Pitoiset F., Jebbawi F. et al. Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy. Front. Immunol. - 2015 Apr 15; 6: 171.

24. Eusebio M., Kuna P., Kraszula L. et al. The relative values of CD8+CD25+Foxp3brigh Treg cells correlate with selected lung function parameters in asthma. Int. J. Immunopathol. Pharmacol. - 2015 Jun; 28 (2): 218-26.

25. Correale J., Villa A. Role of CD8+ CD25+ Foxp3+regulatory T cells in multiple sclerosis. Ann. Neurol. - 2010 May; 67 (5): 625-38.

26. Brimnes J., Allez M., Dotan I. et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J. Immunol. - 2005 May 1; 174 (9): 5814-22.

27. Yao Y., Han W., Liang J. et al. Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8+ regulatory cells. Eur. J. Immunol. - 2013 Jan; 43 (1): 125-36.

28. Han Y., Guo Q., Zhang M. et al. CD69+ CD4+CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J. Immunol. - 2009 Jan 1; 182 (1): 111-20.

29. Zhu J., Feng A., Sun J. et al. Increased CD4(+)CD69(+) CD25(-) T cells in patients with hepatocellular carcinoma are associated with tumor progression. J. Gastroenterol. Hepatol. - 2011 Oct; 26 (10): 1519-26.

30. Xu D., Wang F.S. Are non-traditional CD4(+)CD69(+) CD25(-) regulatory T cells involved in disease progression of human hepatocellular carcinoma? J. Gastroenterol. Hepatol. - 2011 Oct; 26 (10): 1469-70.

31. Han Y., Yang Y., Chen Z. et al. Human hepatocellular carcinoma-infiltrating CD4+CD69+ Foxp3-regulatory T cell suppresses T cell response via membrane-bound TGF-ß1. J. Mol. Med. (Berl). - 2014 May; 92 (5): 539-50.

32. Yu H., Shen Y., Hong J. et al. The contribution of TGF-ß in Epithelial-Mesenchymal Transition (EMT): Down-regulation of E-cadherin via snail. Neoplasma. -2015; 62 (1): 1-15.

33. Lv N., Gao Y., Guan H. et al. Inflammatory mediators, tumor necrosis factor-а and interferon-y, induce EMT in human PTC cell lines. Oncol. Lett. - 2015 Oct; 10 (4): 2591-97.

34. Liu C.Y., Xu J.Y., Shigh X.Y. et al. M2-polarized tumor-associated macrophages promoted epithelialmesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab. Invest. - 2013 Jul; 93 (7): 844-54.

35. Wendt E., Keshav S. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp. Gastroenterol. - 2015; Apr 7; 8: 119-30.

36. Shale M., Schighering C., Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol. Rev. -2013 Mar; 252 (1): 164-82.

37. Giudici F., Maggi L., Santi R. et al. Perianal Crohn’s disease and highdradenitis suppurativa: a possible common immunological scenario. Clin. Mol. Allergy. - 2015 Jul 22; 13 (1): 12.

38. Siegmund B., Feakins R.M., Barmias G. et al. Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. J Crohns Colitis. - 2016 Apr; 10 (4): 377-86.

39. Maggi L., Capone M., Giudici F. et al. CD4+CD161 + T lymphocytes infiltrate Crohn’s disease-associated perianal fistulas and are reduced by anti-TNF-а local therapy. Int. Arch. Allergy Immunol. - 2013; 161 (1) : 81-6.